{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Nayak SS"],"pubmed_abstract":["<h4>Background</h4>Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with an increased risk of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors. However, the prevalence of MetS in AS remains uncertain. This meta-analysis estimates the global prevalence of MetS in AS patients and identifies factors contributing to its variability.<h4>Methods</h4>A systematic search of PubMed, Scopus, Embase, and Web of Science was conducted for studies published up to January 18, 2024. A random-effects model was used to estimate pooled prevalence, while meta-regression and subgroup analyses explored sources of heterogeneity.<h4>Results</h4>Seventeen studies meeting the eligibility criteria were included. The pooled prevalence of MetS in AS patients was 15.5% (95% c"],"journal":["Diabetology & metabolic syndrome"],"pagination":["158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12082907"],"repository":["biostudies-literature"],"pubmed_title":["Prevalence of metabolic syndrome in ankylosing spondylitis: a multi national meta-analysis study."],"pmcid":["PMC12082907"],"pubmed_authors":["Keetha NR","Agyeman KB","Sahli Y","Jafari M","Hashemi M","Shafi N","Amini-Salehi E","Nayak SS","Janani KV","Biswas P","Lichahi MA"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence of metabolic syndrome in ankylosing spondylitis: a multi national meta-analysis study.","description":"<h4>Background</h4>Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with an increased risk of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors. However, the prevalence of MetS in AS remains uncertain. This meta-analysis estimates the global prevalence of MetS in AS patients and identifies factors contributing to its variability.<h4>Methods</h4>A systematic search of PubMed, Scopus, Embase, and Web of Science was conducted for studies published up to January 18, 2024. A random-effects model was used to estimate pooled prevalence, while meta-regression and subgroup analyses explored sources of heterogeneity.<h4>Results</h4>Seventeen studies meeting the eligibility criteria were included. The pooled prevalence of MetS in AS patients was 15.5% (95% c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-11T05:11:39.488Z","creation":"2026-06-11T03:07:44.31Z"},"accession":"S-EPMC12082907","cross_references":{"pubmed":["40380271"],"doi":["10.1186/s13098-025-01720-w"]}}